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Abstract 
Peritoneal carcinomatosis is a well-known factor of poor prognosis in patients with digestive 
adenocarcinomas. Peritoneal dissemination may also occur in midgut well-differentiated 
neuroendocrine tumors, but its influence on survival is ill-defined. We report here the 
history of a 64-year-old woman who had a neuroendocrine tumor of the cecum with 
multiple synchronous metastases in the liver and diffuse peritoneal carcinomatosis. She 
underwent surgical resection of the primary tumor and cytoreduction of liver metastases, 
and received subsequently chemotherapy and somatostatin analogs. In spite of the 
widespread extension of the disease, she survived for 13 years and died from a carcinoid 
heart disease. We discuss the natural history and prognostic factors in patients with midgut 
well-differentiated neuroendocrine tumors, with a focus on the impact of the peritoneal 
carcinomatosis. 
 
Introduction 
Well-differentiated digestive neuroendocrine tumors (NETs) of midgut origin are 
usually of slow course. Mean global survival is 6.6 years, and the 5-year survival rate 
exceeds 60% when pooling all stages [1–4]. Poor prognostic factors have been well 
identified [3–6]: male gender, age >50 years, jejuno-ileal localization, tumor size ≥2 cm, 
tumor depth (ENETS [7] and UICC staging [8]), presence of symptoms upon discovery  
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(such as carcinoid syndrome) and distant metastases. Depending on the presence or 
absence of metastases, 5-year survival rates are respectively of 47 and 73% [1, 4]. The 
Ki67 proliferation index is a major element of the 2010 WHO classification of digestive 
NETs [7, 9], and other histological prognostic factors are vascular invasion and 
presence of necrosis. Multiplicity of primitive tumors seems also to be predictive of a 
distant spreading and poor prognosis [10]. Some studies have suggested that a high 
level of hormonal secretion is a pejorative factor [4]. The prognosis of these patients 
might also be influenced by the occurrence of other syndromes or metachronous 
cancers (colorectal, bladder, endometrial or ovarian carcinomas) that occur in 22 or 
10% of patients, respectively [3]. Finally, survival is influenced by the risk of terminal 
right heart failure due to carcinoid tricuspid valve insufficiency depending on the 
degree of metastatic involvement of the liver. 
We report here a case of prolonged survival in a patient who had a well-
differentiated NET of the midgut with peritoneal dissemination, and discuss the 
prognostic impact of peritoneal carcinomatosis (PC) in NETs. 
Case Report 
A 64-year-old woman was referred to our institution in September 1991 for abdominal pain 
located in the right hypochondrium and nausea without any other symptom. Abdominal ultrasound 
followed by CT scan showed three nodular lesions in the left liver lobe, measuring 3 cm in diameter. A 
percutaneous biopsy was performed and histological analysis showed a well-differentiated NET. 
Upper gastrointestinal endoscopy was normal. Colonoscopy showed a large occlusive tumor whose 
biopsies were identical to the liver tumor. Urinary 5HIAA was four times the upper limit value of 
normal (N). 
A laparoscopy was performed in October 1991. The exploration found bilobar liver metastases 
and a diffuse PC consisting of hundreds of nodules (the largest >3 cm in diameter), corresponding to 
unresectable stage IV carcinomatosis according to Gilly’s classification. The ileocolic region and the 
right colon were resected, and cytoreductive surgery of the metastases located in left liver was 
performed, consisting in a partial left hepatectomy. Histopathological examination of the resected 
segment of the bowel showed multiple well-differentiated NETs, with Ki67 at 12%. The largest bowel 
tumor measured 30 mm in diameter and was located 1 cm above to the ileocolic valve, with invasion 
of the visceral peritoneum (T4 according to ENETS-TNM [7] or UICC-TNM [8] staging, and G2 
according to WHO grading [7, 9]). Three other smaller and less infiltrative tumors (5–10 mm in 
diameter) were found at the appendix base. Pathological analysis confirmed the diffuse both 
macroscopical and microscopical PC. Examination of the liver resection specimen showed multiple 
metastases with similar histological features and surrounding hepatic tissue was normal. 
There were no postoperative complications and tumor markers returned to normal values. 
Adjuvant chemotherapy was decided after a CT scan reference evaluation that showed six residual 
hepatic metastases. The patient received 12 cycles of 5-fluorouracil (400 mg/m2/day for 5 days) 
combined with streptozotocin (500 mg/m2/day for 5 days) with good tolerance. At evaluation, there 
was a regression of the hepatic metastasis exceeding 30%. Chemotherapy was stopped and then 
followed by lanreotide administration (one intramuscular injection of 30 mg every 10 days) during 
12 months, with the aim of controlling both recurrent hormonal hypersecretion and tumor growth. 
The patient did not report any symptoms, particularly no flushing or diarrhea, and physical 
examination was normal; lanreotide was stopped in 1994. CT scan and magnetic resonance imaging 
follow-up showed six stable tumors in the right liver. Tumor markers remained at a normal level. 
Between 1994 and 2000, the patient was followed every 6 months. A watery diarrhea appeared in 
2000, associated with pelvic pain without flushing. At abdominal palpation there was a mass located 
in the left hypogastric area, also found at vaginal touch. Tumor markers had increased (urinary 5HIAA 
21 N, chromogranin-A 74 N). Somatostatin receptor scintigraphy showed uptake in the remaining 
liver, the peritoneum and the pelvic region, corresponding to metachronous metastasis of the left  
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ovary. A hysterectomy with bilateral ovariectomy was performed. Pathological examination showed a 
diffuse metastatic invasion of both right and left ovaries, measuring respectively 40 and 130 mm in 
diameter. The residual tumor consisted in PC and metastases located in the right and residual left 
liver. Postoperatively, tumor markers decreased (urinary 5HIAA 5 N, chromogranin-A 5 N). 
Abdominal CT scan showed stable liver lesions. 
In 2002, the patient complained of asthenia with a loss of 10 kg in 6 months, diarrhea and 
abdominal pain suggesting König’s syndrome. Biological markers were as follows: urinary 5HIAA 
15 N, chromogranin-A 14 N. A CT scan confirmed a 30% progression of liver metastases according 
to the RECIST criteria. Eight cycles of a second-line chemotherapy combining doxorubicin 
(60 mg/m2/day) and dacarbazine (150 mg/m2/day) were administered between March 2002 and 
January 2003. Ankle and leg edema with distended jugular veins were noted, suggesting right heart 
failure. A tricuspid murmur was heard at cardiac auscultation. Transthoracic cardiac ultrasonography 
showed a stage IV carcinoid tricuspid valve insufficiency. The right cavities were dilated with 
moderate reflux in the inferior cava vein, pulmonary arterial pressure was 38 mm Hg and left 
ventricular ejection fraction was 57% (cardiac ultrasonography had been normal in 2000). 
Somatostatin (200 µg × 3 per day, subcutaneous) was then given and led to clinical improvement. 
Tumor burden remained stable. In July 2004, an acute deterioration of her terminal right heart failure 
occurred and the patient died, 13 years after initial diagnosis of the digestive NET with PC. 
Discussion 
Peritoneal involvement is uncommon in digestive NETs, including well-
differentiated midgut NETs, and data about its prevalence, prognostic signification 
and management are scarce. PC is less common in digestive NETs than in 
adenocarcinomas and occurs more frequently in NETs of midgut origin than in those 
of gastropancreatic (foregut) origin [6, 11]. CT scan likely has insufficient sensitivity 
for diagnosis, and data about the prevalence of PC come from surgical series. Recently, 
the ENETS consensus guidelines for the management of peritoneal carcinomatosis 
from neuroendocrine tumors [12] have reported a 13% prevalence of PC in patients 
with midgut NETs at the time of diagnosis. The prevalence of PC seems to be higher 
(19–33%) in well-differentiated NETs [1, 11–13]. Ileal location of the primary tumor 
and liver dissemination are associated with the presence of PC. A gravity PC score 
(table 1) has been recently proposed to evaluate the importance of intra-abdominal 
metastatic diffusion [12]. Based on Gilly’s classification (table 2), it quantifies 
preoperatively the extent of the disease within each region of the abdomen and pelvis, 
and includes the grading of lymph nodes and liver metastases. 
The influence of peritoneal involvement in the survival of patients with NETs is 
unclear. Our group previously reported a series of 116 cases of digestive NETs, 
including 30 midgut NETs [11]. PC was present in 11 patients (10%): 8 of the 30 
midgut tumors and 3 from non-gastrinoma pancreatic tumors. In patients with midgut 
well-differentiated NETs, 5-year survival rates were 64 and 76% in patients with and 
without PC, respectively (p > 0.05). Similarly, Boudreaux et al. [14] reported 4-year 
actuarial survival rates of 44 and 61% in patients with and without PC, respectively 
(p = 0.15). Whereas statistical significance was not reached in these two studies 
possibly due to a limited number of patients, it is not excluded that PC could be an 
independent pejorative prognostic factor in digestive NETs. 
The management of PC in midgut well-differentiated NETs is not consensual. 
Whereas diffuse adenocarcinomatous PC is usually considered as a contraindication 
for surgical resection, the better prognosis of digestive NETs should make us  
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systematically consider surgery as a therapeutic option. Aggressive surgical resections 
of the peritoneal involvement are under evaluation. Boudreaux et al. [14] reported a 
series of 82 advanced-stage NET patients who underwent a surgical procedure to 
determine the extent of disease and perform debulking. Peritoneal extension was 
present in 47.6%. Debulking hepatic or other visceral metastases by resection, 
radiofrequency ablation, or combination led to improvement of symptoms in 91.5% of 
patients, and overall 4-year actuarial survival was 55%. Elias et al. [13] reported 5-year 
survival rates of 40.9 and 66.2% in 20 patients undergoing a resection of PC for bowel 
obstruction, and in 17 patients undergoing ‘maximal’ cytoreductive surgery followed by 
immediate intraperitoneal chemotherapy with various combinations of mitomycin C, 
5-fluorouracil, oxaliplatin and irinotecan, respectively (p = 0.007). In our observation, 
we used somatostatin analogs to slow tumor progression, as recently documented in 
the PROMID study [15], which showed a 67% reduction in the risk of disease 
progression with octreotide LAR versus placebo. This study suggested that octreotide 
LAR might be considered as a treatment option in patients with well-differentiated 
midgut NETs and limited liver tumor burden (≤10%). 
Whereas PC in adenocarcinomas leads to many symptoms and complications, such 
as abdominal pain, ascitis and bowel obstruction, these symptoms seem to be unusual 
in patients with well-differentiated midgut NETs. Our group previously reported that 
life expectancy was not affected by PC [11]. In contrast, carcinoid heart disease is a 
major prognostic factor, whose specific management could significantly improve both 
survival and patient’s quality of life. Carcinoid heart disease can be found in about 50% 
of patients with carcinoid syndrome, but it is symptomatic in only 10% [16]. 
Performing a cardiac ultrasound is thus justified in all patients with NETs and 
serotonin secretion, even if the carcinoid syndrome is incomplete [17]. Surgical 
replacement of the tricuspid valve should be discussed in case of symptomatic and 
severe right heart failure. 
In conclusion, the presence of PC does not seem to impair survival by itself. It should 
not be considered as a contraindication for aggressive therapeutic strategy, such as 
extended loco-regional surgical resection of the tumor, hepatic metastases and 
carcinomatosis nodules. Whether combining aggressive surgery with chemotherapy 
(systemic/intraperitoneal) might improve overall survival and progression-free 
survival in these patients warrants further studies. Finally, targeted biotherapies such 
as sunitinib and everolimus, which have shown anti-tumor activity in pancreatic NETs 
[18, 19], should be further evaluated in unresectable well-differentiated metastatic 
NETs of midgut origin. 
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Table 1. ENETS gravity PC grading system based on the association of PC with lymph node and liver 
metastases [12] 
                      0 points  1 point  2 points  3 points 
                    Lymph node  
metastases 
local (primary tumor relay)  regional (secondary tumor 
drainage territory relay) 
distant abdominal (hepatic 
pedicle, retroperitoneal) 
extra-abdominal 
                    Liver  
metastases 
no macroscopic nodule  one lobe 
<5 nodules 
both lobes 
5–10 nodules 
both lobes 
>10 nodules 
                    PC  no macroscopic nodule  Gilly I–II resectable  Gilly III–IV resectable  Gilly unresectable 
                    Grade A: 0–3 points; grade B: 4–6 points; grade C: 7–9 points. 
     
 
Table 2. Gilly’s classification based on nodule size and simplified extent of intraperitoneal 
dissemination [12] 
        Stage 0  no macroscopic disease 
Stage I  malignant granulations <5 mm in diameter localized in one part of the abdomen 
Stage II  malignant granulations <5 mm in diameter diffuse to the whole abdomen 
Stage III  localized or diffuse malignant granulations 5–20 mm in diameter 
Stage IV  localized or diffuse large malignant masses (>2 cm in diameter) 
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